NCT06943586 Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
| NCT ID | NCT06943586 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-04-09 |
| Primary Completion | 2028-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-04-09 with a primary completion date of 2028-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Eligibility Criteria
Inclusion Criteria: * Patients 18-89 years of age * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well) Exclusion Criteria: * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%) * prescribed anticoagulation prior to stroke * treated with intravenous thrombolysis * treated with mechanical thrombectomy * missing NIH Stroke Scale score
Contact & Investigator
Ekaterina Bakradze, MD
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT06943586 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06943586 currently recruiting?
Yes, NCT06943586 is actively recruiting participants. Contact the research team at ebakradze@uabmc.edu for enrollment information.
Where is the NCT06943586 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT06943586 clinical trial?
NCT06943586 is sponsored by University of Alabama at Birmingham. The principal investigator is Ekaterina Bakradze, MD at University of Alabama at Birmingham. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.